These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37855359)

  • 1. Recent Updates on Nanocarriers for Drug Delivery in Posterior Segment Diseases with Emphasis on Diabetic Retinopathy.
    Parashar R; Vyas A; Sah AK; Hemnani N; Thangaraju P; Suresh PK
    Curr Diabetes Rev; 2024; 20(6):e171023222282. PubMed ID: 37855359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in Ocular Drug Delivery, with Special Emphasis on Lipid Based Nanocarriers.
    Sah AK; Suresh PK
    Recent Pat Nanotechnol; 2015; 9(2):94-105. PubMed ID: 27009124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chitosan as a promising materials for the construction of nanocarriers for diabetic retinopathy: an updated review.
    Lv Y; Zhai C; Sun G; He Y
    J Biol Eng; 2024 Feb; 18(1):18. PubMed ID: 38388386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of lipid nanoparticles to ocular drug delivery.
    Battaglia L; Serpe L; Foglietta F; Muntoni E; Gallarate M; Del Pozo Rodriguez A; Solinis MA
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1743-1757. PubMed ID: 27291069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patent perspectives for corticosteroids based ophthalmic therapeutics.
    Suresh PK; Sah AK
    Recent Pat Drug Deliv Formul; 2014; 8(3):206-23. PubMed ID: 25020063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review on recent drug delivery systems for posterior segment of eye.
    Nayak K; Misra M
    Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-invasive nanoparticle mediated delivery of triamcinolone acetonide ameliorates diabetic retinopathy in rats.
    Mahaling B; Srinivasarao DA; Raghu G; Kasam RK; Bhanuprakash Reddy G; Katti DS
    Nanoscale; 2018 Sep; 10(35):16485-16498. PubMed ID: 29897081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluocinolone acetonide implantable device for diabetic retinopathy.
    Schwartz SG; Flynn HW
    Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy.
    Selvaraj K; Gowthamarajan K; Karri VV; Barauah UK; Ravisankar V; Jojo GM
    J Drug Target; 2017 Jun; 25(5):386-405. PubMed ID: 28122462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy.
    Yilmaz T; Cordero-Coma M; Lavaque AJ; Gallagher MJ; Padula WV
    Curr Pharm Biotechnol; 2011 Mar; 12(3):337-46. PubMed ID: 20939800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to prolong the residence time of drug delivery systems on ocular surface.
    Grassiri B; Zambito Y; Bernkop-Schnürch A
    Adv Colloid Interface Sci; 2021 Feb; 288():102342. PubMed ID: 33444845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits.
    Chetoni P; Burgalassi S; Monti D; Tampucci S; Tullio V; Cuffini AM; Muntoni E; Spagnolo R; Zara GP; Cavalli R
    Eur J Pharm Biopharm; 2016 Dec; 109():214-223. PubMed ID: 27789355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanocarriers Based Ocular Therapeutics: Updates, Challenges and Future Prospectives.
    Kaushal U; Kaur M; Nagpal M; Bhuyan M; Gounder KP
    Curr Drug Res Rev; 2023; 15(1):15-28. PubMed ID: 36100986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent trends in drug-delivery systems for the treatment of diabetic retinopathy and associated fibrosis.
    Silva M; Peng T; Zhao X; Li S; Farhan M; Zheng W
    Adv Drug Deliv Rev; 2021 Jun; 173():439-460. PubMed ID: 33857553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective for Diagnosis and Treatment of Diabetic Retinopathy.
    Himasa FI; Singhal M; Ojha A; Kumar B
    Curr Pharm Des; 2022; 28(7):560-569. PubMed ID: 34781866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
    Qiu F; Meng T; Chen Q; Zhou K; Shao Y; Matlock G; Ma X; Wu W; Du Y; Wang X; Deng G; Ma JX; Xu Q
    Mol Pharm; 2019 May; 16(5):1958-1970. PubMed ID: 30912953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic-Coated Albumin Nanoparticles for the Non-Invasive Delivery of Apatinib in Diabetic Retinopathy.
    Radwan SE; El-Kamel A; Zaki EI; Burgalassi S; Zucchetti E; El-Moslemany RM
    Int J Nanomedicine; 2021; 16():4481-4494. PubMed ID: 34239300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current nanotechnology approaches for the treatment and management of diabetic retinopathy.
    Fangueiro JF; Silva AM; Garcia ML; Souto EB
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):307-22. PubMed ID: 25536109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers.
    de Oliveira IF; Barbosa EJ; Peters MCC; Henostroza MAB; Yukuyama MN; Dos Santos Neto E; Löbenberg R; Bou-Chacra N
    Int J Pharm; 2020 Nov; 589():119831. PubMed ID: 32877729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.